Abstract
Fourteen hemodialysis patients were selected to receive once every other week darbepoetin alfa in substitution for weekly subcutaneously administered epoetin alfa. All patients included in the analysis were male veterans over the age of 18 on established and unchanging doses of subcutaneous erythropoietin alfa and on hemodialysis for at least 3 months. All patients had sufficient iron stores, defined as serum ferritin concentrations of greater than 100 mcg/L. Patients were converted to darbepoetin alfa using the manufacturer's conversion chart. Doses of darbepoetin alfa were adjusted to maintain a hemoglobin concentration greater than 11 to 12 g/dL and a hematocrit greater than 33% to 36%. Patients were followed for 4 months and evaluated for efficacy. Hemoglobin, hematocrit, and serum ferritin levels were measured at baseline and repeated every month. Among the 12 patients completing the study 12 dose increases of darbepoetin alfa were needed. Switching these 12 patients from erythropoietin alfa to darbepoetin alfa was projected to increase acquisition cost by more than $36,000, assuming that these patients remained on their current doses of darbepoetin alfa for 1 year. The authors concluded that darbepoetin alfa should not be used in patients with anemia caused by chronic renal failure who require hemodialysis until further studies support this use.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.